Advertisement
Advertisement

TNGX

TNGX logo

Tango Therapeutics, Inc.

11.61
USD
Sponsored
-0.06
-0.49%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

11.61

0.00
-0.03%

TNGX Earnings Reports

Positive Surprise Ratio

TNGX beat 11 of 17 last estimates.

65%

Next Report

Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$638.01K
/
-$0.32
Implied change from Q3 25 (Revenue/ EPS)
-98.81%
/
-328.57%
Implied change from Q4 24 (Revenue/ EPS)
-84.50%
/
-8.57%

Tango Therapeutics, Inc. earnings per share and revenue

On Nov 04, 2025, TNGX reported earnings of 0.14 USD per share (EPS) for Q3 25, beating the estimate of -0.05 USD, resulting in a 360.22% surprise. Revenue reached 53.81 million, compared to an expected 37.88 million, with a 42.04% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 638.01 thousand USD, implying an decrease of -328.57% EPS, and decrease of -98.81% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Tango Therapeutics, Inc. reported EPS of $0.14, beating estimates by 360.22%, and revenue of $53.81M, 42.04% above expectations.
The stock price moved -- 0%, changed from $8.01 before the earnings release to $8.01 the day after.
The next earning report is scheduled for Feb 25, 2026.
Based on 12 analysts, Tango Therapeutics, Inc. is expected to report EPS of -$0.32 and revenue of $638.01K for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement